Pharma RSS Digest - 2026-08-23
Overview
The current pharma and health tape is light, centered on a device-safety action and a pre-launch consumer oral-care campaign. The FDA’s alert on certain Medical Action Industries epidural kits is the most consequential item because a component problem can propagate through assembled procedure trays and potentially cause serious harm. No serious injuries or deaths had been reported as of July 23. LumenStim’s announcement is not an FDA approval; it received permission to launch a crowdfunding campaign that had not yet gone live. Overall, the surviving signal is narrow rather than evidence of a broader sector shift.
Key Developments
The FDA issued an Early Alert covering 15 lots across three Medical Action Industries epidural kit models because they may contain sodium chloride flush ampules subject to a Huons/Spectra recall. Customers should quarantine the kits, discard the ampules, and relabel the remaining components, which may continue to be used. Watch for a formal recall classification, additional FDA updates, completion of inventory checks, and any reports of patient harm.
LumenStim said Kickstarter approved its planned launch of a peroxide-free whitening system combining sonic brushing with a dual-chamber toothpaste and nano-hydroxyapatite. The concept could appeal to consumers seeking a gentler, shorter oral-care routine, but the cited study involved 14 users of the prior-generation product, not the product now being launched. Watch for the campaign’s timing and pricing, evidence for the next-generation system, patent progress, and any move beyond crowdfunding.
Watchlist
- HCN Global and the Society for Health Communication are expanding a free webinar series on preventive care, maternal and reproductive health, mental health, and community resilience. The first session is scheduled for August 28, but no measurable policy or health-outcome targets were provided. [link]